tiprankstipranks
Advertisement
Advertisement

RNAC Stock Latest News

Cartesian Therapeutics: Late-Stage Descartes-08 De-Risking and 2027 Data Wave Underpin Van Buren’s Buy Rating
RatingsCartesian Therapeutics: Late-Stage Descartes-08 De-Risking and 2027 Data Wave Underpin Van Buren’s Buy Rating
11d ago
RNAC
Buy Rating Reiterated on Strong Cash Runway and Near‑Term Clinical Catalysts; $40 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on Strong Cash Runway and Near‑Term Clinical Catalysts; $40 Price Target Maintained
12d ago
RNAC
Cartesian Therapeutics Shareholders Back Directors and Governance Measures
PremiumCompany Announcements
Cartesian Therapeutics Shareholders Back Directors and Governance Measures
2M ago
8K
RNAC
Reiterating Buy on Cartesian: WestGene LNP Deal Expands In Vivo Pipeline and Catalyzes Long-Term Growth
PremiumRatings
Reiterating Buy on Cartesian: WestGene LNP Deal Expands In Vivo Pipeline and Catalyzes Long-Term Growth
2M ago
RNAC
Selecta Biosciences Inc trading resumes
PremiumThe Fly
Selecta Biosciences Inc trading resumes
2M ago
RNAC
Selecta Biosciences Inc trading halted, volatility trading pause
PremiumThe FlySelecta Biosciences Inc trading halted, volatility trading pause
2M ago
RNAC
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance
Premium
Company Announcements
Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance
2M ago
8K
RNAC
Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures
Premium
The Fly
Cartesian Therapeutics secures up to $150M financing from K2 HealthVentures
3M ago
RNAC
Cartesian Secures Major Loan Facility to Extend Runway
PremiumCompany Announcements
Cartesian Secures Major Loan Facility to Extend Runway
3M ago
8K
RNAC
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
PremiumThe Fly
Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
3M ago
RNAC
Cartesian Therapeutics management to meet with BTIG
PremiumThe Fly
Cartesian Therapeutics management to meet with BTIG
4M ago
RNAC
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
PremiumRatings
Buy Rating on Cartesian Therapeutics (RNAC) Driven by Strong Strategic Vision, Clinical Roadmap, and Attractive Risk‑Reward Profile
4M ago
RNAC
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
PremiumCompany AnnouncementsCartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation
5M ago
8K
RNAC
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
Premium
Company Announcements
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch
5M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
Premium
The Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
5M ago
RNAC
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
PremiumThe Fly
Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
5M ago
RNAC
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
PremiumRatings
Cartesian Therapeutics: Reaffirmed AURORA Timelines and Solid Cash Runway Underpin Needham Buy Rating and $42 Target
5M ago
RNAC
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
PremiumThe Fly
Cartesian Therapeutics reports FY25 EPS ($5.02), consensus ($2.35)
5M ago
RNAC
RNAC Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RNAC Upcoming Earnings Report: What to Expect?
6M ago
RNAC
Cartesian Therapeutics announces employment inducement grants
PremiumThe FlyCartesian Therapeutics announces employment inducement grants
7M ago
RNAC
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
Premium
Company Announcements
Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress
7M ago
8K
RNAC
Cartesian Therapeutics highlights recent progress, outlines 2026
Premium
The Fly
Cartesian Therapeutics highlights recent progress, outlines 2026
7M ago
RNAC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >